nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—CYP1A2—chronic obstructive pulmonary disease	0.731	1	CbGaD
Guanabenz—Cough—Montelukast—chronic obstructive pulmonary disease	0.00041	0.00177	CcSEcCtD
Guanabenz—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000409	0.00176	CcSEcCtD
Guanabenz—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000408	0.00176	CcSEcCtD
Guanabenz—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000407	0.00176	CcSEcCtD
Guanabenz—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000407	0.00176	CcSEcCtD
Guanabenz—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000407	0.00175	CcSEcCtD
Guanabenz—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000407	0.00175	CcSEcCtD
Guanabenz—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000406	0.00175	CcSEcCtD
Guanabenz—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000403	0.00174	CcSEcCtD
Guanabenz—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.000403	0.00174	CcSEcCtD
Guanabenz—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.0004	0.00173	CcSEcCtD
Guanabenz—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.0004	0.00173	CcSEcCtD
Guanabenz—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000399	0.00172	CcSEcCtD
Guanabenz—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000399	0.00172	CcSEcCtD
Guanabenz—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000399	0.00172	CcSEcCtD
Guanabenz—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000398	0.00172	CcSEcCtD
Guanabenz—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000397	0.00171	CcSEcCtD
Guanabenz—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.000395	0.00171	CcSEcCtD
Guanabenz—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000395	0.0017	CcSEcCtD
Guanabenz—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000391	0.00169	CcSEcCtD
Guanabenz—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000391	0.00169	CcSEcCtD
Guanabenz—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000391	0.00169	CcSEcCtD
Guanabenz—Infection—Formoterol—chronic obstructive pulmonary disease	0.000389	0.00168	CcSEcCtD
Guanabenz—Infection—Arformoterol—chronic obstructive pulmonary disease	0.000389	0.00168	CcSEcCtD
Guanabenz—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.00166	CcSEcCtD
Guanabenz—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.00166	CcSEcCtD
Guanabenz—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000386	0.00166	CcSEcCtD
Guanabenz—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000385	0.00166	CcSEcCtD
Guanabenz—Pulmonary oedema—Prednisone—chronic obstructive pulmonary disease	0.000384	0.00166	CcSEcCtD
Guanabenz—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00166	CcSEcCtD
Guanabenz—Nervous system disorder—Formoterol—chronic obstructive pulmonary disease	0.000384	0.00166	CcSEcCtD
Guanabenz—Nervous system disorder—Arformoterol—chronic obstructive pulmonary disease	0.000384	0.00166	CcSEcCtD
Guanabenz—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000383	0.00165	CcSEcCtD
Guanabenz—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000383	0.00165	CcSEcCtD
Guanabenz—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000382	0.00165	CcSEcCtD
Guanabenz—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000382	0.00165	CcSEcCtD
Guanabenz—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000381	0.00164	CcSEcCtD
Guanabenz—Infection—Montelukast—chronic obstructive pulmonary disease	0.000381	0.00164	CcSEcCtD
Guanabenz—Skin disorder—Arformoterol—chronic obstructive pulmonary disease	0.00038	0.00164	CcSEcCtD
Guanabenz—Skin disorder—Formoterol—chronic obstructive pulmonary disease	0.00038	0.00164	CcSEcCtD
Guanabenz—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000379	0.00163	CcSEcCtD
Guanabenz—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000377	0.00163	CcSEcCtD
Guanabenz—Hyperkinesia—Prednisone—chronic obstructive pulmonary disease	0.000377	0.00162	CcSEcCtD
Guanabenz—Nervous system disorder—Montelukast—chronic obstructive pulmonary disease	0.000376	0.00162	CcSEcCtD
Guanabenz—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000375	0.00162	CcSEcCtD
Guanabenz—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000375	0.00162	CcSEcCtD
Guanabenz—Skin disorder—Montelukast—chronic obstructive pulmonary disease	0.000372	0.00161	CcSEcCtD
Guanabenz—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.00037	0.00159	CcSEcCtD
Guanabenz—Infection—Salbutamol—chronic obstructive pulmonary disease	0.000367	0.00158	CcSEcCtD
Guanabenz—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000366	0.00158	CcSEcCtD
Guanabenz—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000366	0.00158	CcSEcCtD
Guanabenz—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000364	0.00157	CcSEcCtD
Guanabenz—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000364	0.00157	CcSEcCtD
Guanabenz—Nervous system disorder—Salbutamol—chronic obstructive pulmonary disease	0.000362	0.00156	CcSEcCtD
Guanabenz—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000361	0.00156	CcSEcCtD
Guanabenz—Diabetes mellitus—Prednisone—chronic obstructive pulmonary disease	0.00036	0.00155	CcSEcCtD
Guanabenz—Skin disorder—Salbutamol—chronic obstructive pulmonary disease	0.000359	0.00155	CcSEcCtD
Guanabenz—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000357	0.00154	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000357	0.00154	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000357	0.00154	CcSEcCtD
Guanabenz—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000352	0.00152	CcSEcCtD
Guanabenz—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.000352	0.00152	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000349	0.00151	CcSEcCtD
Guanabenz—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000349	0.00151	CcSEcCtD
Guanabenz—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000349	0.00151	CcSEcCtD
Guanabenz—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000345	0.00149	CcSEcCtD
Guanabenz—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000345	0.00149	CcSEcCtD
Guanabenz—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000345	0.00149	CcSEcCtD
Guanabenz—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000344	0.00149	CcSEcCtD
Guanabenz—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.000343	0.00148	CcSEcCtD
Guanabenz—Injury—Prednisone—chronic obstructive pulmonary disease	0.000341	0.00147	CcSEcCtD
Guanabenz—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.00034	0.00147	CcSEcCtD
Guanabenz—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000339	0.00146	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Formoterol—chronic obstructive pulmonary disease	0.000338	0.00146	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Arformoterol—chronic obstructive pulmonary disease	0.000338	0.00146	CcSEcCtD
Guanabenz—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000337	0.00146	CcSEcCtD
Guanabenz—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000337	0.00146	CcSEcCtD
Guanabenz—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000337	0.00146	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000337	0.00145	CcSEcCtD
Guanabenz—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000335	0.00144	CcSEcCtD
Guanabenz—Pain—Formoterol—chronic obstructive pulmonary disease	0.000335	0.00144	CcSEcCtD
Guanabenz—Pain—Arformoterol—chronic obstructive pulmonary disease	0.000335	0.00144	CcSEcCtD
Guanabenz—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000335	0.00144	CcSEcCtD
Guanabenz—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000332	0.00143	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Montelukast—chronic obstructive pulmonary disease	0.000331	0.00143	CcSEcCtD
Guanabenz—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000331	0.00143	CcSEcCtD
Guanabenz—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000329	0.00142	CcSEcCtD
Guanabenz—Pain—Montelukast—chronic obstructive pulmonary disease	0.000328	0.00141	CcSEcCtD
Guanabenz—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000327	0.00141	CcSEcCtD
Guanabenz—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000325	0.0014	CcSEcCtD
Guanabenz—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000324	0.0014	CcSEcCtD
Guanabenz—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000324	0.0014	CcSEcCtD
Guanabenz—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000323	0.00139	CcSEcCtD
Guanabenz—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000323	0.00139	CcSEcCtD
Guanabenz—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000322	0.00139	CcSEcCtD
Guanabenz—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000321	0.00139	CcSEcCtD
Guanabenz—Cardiac failure—Prednisone—chronic obstructive pulmonary disease	0.000321	0.00139	CcSEcCtD
Guanabenz—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000321	0.00138	CcSEcCtD
Guanabenz—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00138	CcSEcCtD
Guanabenz—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00138	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Salbutamol—chronic obstructive pulmonary disease	0.000319	0.00138	CcSEcCtD
Guanabenz—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000319	0.00137	CcSEcCtD
Guanabenz—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00136	CcSEcCtD
Guanabenz—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00136	CcSEcCtD
Guanabenz—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000313	0.00135	CcSEcCtD
Guanabenz—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000311	0.00134	CcSEcCtD
Guanabenz—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000311	0.00134	CcSEcCtD
Guanabenz—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000309	0.00133	CcSEcCtD
Guanabenz—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000309	0.00133	CcSEcCtD
Guanabenz—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000309	0.00133	CcSEcCtD
Guanabenz—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000309	0.00133	CcSEcCtD
Guanabenz—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000308	0.00133	CcSEcCtD
Guanabenz—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000306	0.00132	CcSEcCtD
Guanabenz—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000305	0.00132	CcSEcCtD
Guanabenz—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000305	0.00132	CcSEcCtD
Guanabenz—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000305	0.00131	CcSEcCtD
Guanabenz—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000305	0.00131	CcSEcCtD
Guanabenz—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000304	0.00131	CcSEcCtD
Guanabenz—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000303	0.00131	CcSEcCtD
Guanabenz—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000303	0.00131	CcSEcCtD
Guanabenz—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000303	0.00131	CcSEcCtD
Guanabenz—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.0013	CcSEcCtD
Guanabenz—Haemoglobin—Prednisolone—chronic obstructive pulmonary disease	0.0003	0.00129	CcSEcCtD
Guanabenz—Haemorrhage—Prednisolone—chronic obstructive pulmonary disease	0.000298	0.00129	CcSEcCtD
Guanabenz—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000294	0.00127	CcSEcCtD
Guanabenz—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.00126	CcSEcCtD
Guanabenz—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000292	0.00126	CcSEcCtD
Guanabenz—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00124	CcSEcCtD
Guanabenz—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00124	CcSEcCtD
Guanabenz—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000288	0.00124	CcSEcCtD
Guanabenz—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000287	0.00124	CcSEcCtD
Guanabenz—Hypokalaemia—Prednisone—chronic obstructive pulmonary disease	0.000285	0.00123	CcSEcCtD
Guanabenz—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00122	CcSEcCtD
Guanabenz—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000281	0.00121	CcSEcCtD
Guanabenz—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000281	0.00121	CcSEcCtD
Guanabenz—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000277	0.00119	CcSEcCtD
Guanabenz—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000277	0.00119	CcSEcCtD
Guanabenz—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000275	0.00119	CcSEcCtD
Guanabenz—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000273	0.00118	CcSEcCtD
Guanabenz—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00117	CcSEcCtD
Guanabenz—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00117	CcSEcCtD
Guanabenz—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000268	0.00116	CcSEcCtD
Guanabenz—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000268	0.00116	CcSEcCtD
Guanabenz—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000265	0.00114	CcSEcCtD
Guanabenz—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000262	0.00113	CcSEcCtD
Guanabenz—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00113	CcSEcCtD
Guanabenz—Erythema—Prednisolone—chronic obstructive pulmonary disease	0.00026	0.00112	CcSEcCtD
Guanabenz—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000259	0.00112	CcSEcCtD
Guanabenz—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000259	0.00112	CcSEcCtD
Guanabenz—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000254	0.00109	CcSEcCtD
Guanabenz—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000253	0.00109	CcSEcCtD
Guanabenz—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000249	0.00107	CcSEcCtD
Guanabenz—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000249	0.00107	CcSEcCtD
Guanabenz—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00106	CcSEcCtD
Guanabenz—Rash—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00106	CcSEcCtD
Guanabenz—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000247	0.00106	CcSEcCtD
Guanabenz—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000247	0.00106	CcSEcCtD
Guanabenz—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000247	0.00106	CcSEcCtD
Guanabenz—Headache—Formoterol—chronic obstructive pulmonary disease	0.000245	0.00106	CcSEcCtD
Guanabenz—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000245	0.00106	CcSEcCtD
Guanabenz—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000245	0.00106	CcSEcCtD
Guanabenz—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000245	0.00106	CcSEcCtD
Guanabenz—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000244	0.00105	CcSEcCtD
Guanabenz—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000244	0.00105	CcSEcCtD
Guanabenz—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000244	0.00105	CcSEcCtD
Guanabenz—Rash—Montelukast—chronic obstructive pulmonary disease	0.000242	0.00104	CcSEcCtD
Guanabenz—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000241	0.00104	CcSEcCtD
Guanabenz—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000241	0.00104	CcSEcCtD
Guanabenz—Headache—Montelukast—chronic obstructive pulmonary disease	0.00024	0.00104	CcSEcCtD
Guanabenz—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000237	0.00102	CcSEcCtD
Guanabenz—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00101	CcSEcCtD
Guanabenz—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000234	0.00101	CcSEcCtD
Guanabenz—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.00101	CcSEcCtD
Guanabenz—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000233	0.001	CcSEcCtD
Guanabenz—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000233	0.001	CcSEcCtD
Guanabenz—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000232	0.001	CcSEcCtD
Guanabenz—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000232	0.001	CcSEcCtD
Guanabenz—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000232	0.000999	CcSEcCtD
Guanabenz—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000228	0.000985	CcSEcCtD
Guanabenz—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000228	0.000982	CcSEcCtD
Guanabenz—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000224	0.000967	CcSEcCtD
Guanabenz—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.00022	0.000947	CcSEcCtD
Guanabenz—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000218	0.000942	CcSEcCtD
Guanabenz—Haemoglobin—Prednisone—chronic obstructive pulmonary disease	0.000218	0.00094	CcSEcCtD
Guanabenz—Haemorrhage—Prednisone—chronic obstructive pulmonary disease	0.000217	0.000935	CcSEcCtD
Guanabenz—Connective tissue disorder—Prednisone—chronic obstructive pulmonary disease	0.000213	0.000919	CcSEcCtD
Guanabenz—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000212	0.000914	CcSEcCtD
Guanabenz—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000209	0.0009	CcSEcCtD
Guanabenz—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000207	0.000892	CcSEcCtD
Guanabenz—Eye disorder—Prednisone—chronic obstructive pulmonary disease	0.000203	0.000874	CcSEcCtD
Guanabenz—Immune system disorder—Prednisone—chronic obstructive pulmonary disease	0.000196	0.000845	CcSEcCtD
Guanabenz—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.00019	0.000821	CcSEcCtD
Guanabenz—Erythema—Prednisone—chronic obstructive pulmonary disease	0.000189	0.000814	CcSEcCtD
Guanabenz—Malnutrition—Prednisone—chronic obstructive pulmonary disease	0.000189	0.000814	CcSEcCtD
Guanabenz—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.000782	CcSEcCtD
Guanabenz—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000178	0.000767	CcSEcCtD
Guanabenz—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000175	0.000755	CcSEcCtD
Guanabenz—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000175	0.000754	CcSEcCtD
Guanabenz—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000753	CcSEcCtD
Guanabenz—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000173	0.000748	CcSEcCtD
Guanabenz—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000172	0.000744	CcSEcCtD
Guanabenz—Malaise—Prednisone—chronic obstructive pulmonary disease	0.00017	0.000734	CcSEcCtD
Guanabenz—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000169	0.00073	CcSEcCtD
Guanabenz—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000168	0.000726	CcSEcCtD
Guanabenz—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000166	0.000716	CcSEcCtD
Guanabenz—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.000163	0.000703	CcSEcCtD
Guanabenz—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000693	CcSEcCtD
Guanabenz—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000161	0.000693	CcSEcCtD
Guanabenz—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.00016	0.000691	CcSEcCtD
Guanabenz—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000159	0.000685	CcSEcCtD
Guanabenz—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000674	CcSEcCtD
Guanabenz—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000664	CcSEcCtD
Guanabenz—Infection—Prednisone—chronic obstructive pulmonary disease	0.000153	0.00066	CcSEcCtD
Guanabenz—Shock—Prednisone—chronic obstructive pulmonary disease	0.000152	0.000654	CcSEcCtD
Guanabenz—Nervous system disorder—Prednisone—chronic obstructive pulmonary disease	0.000151	0.000652	CcSEcCtD
Guanabenz—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000649	CcSEcCtD
Guanabenz—Skin disorder—Prednisone—chronic obstructive pulmonary disease	0.00015	0.000645	CcSEcCtD
Guanabenz—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000633	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.00014	0.000605	CcSEcCtD
Guanabenz—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.00014	0.000605	CcSEcCtD
Guanabenz—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000138	0.000597	CcSEcCtD
Guanabenz—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000136	0.000585	CcSEcCtD
Guanabenz—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000134	0.000578	CcSEcCtD
Guanabenz—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000134	0.000577	CcSEcCtD
Guanabenz—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000134	0.000576	CcSEcCtD
Guanabenz—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000133	0.000573	CcSEcCtD
Guanabenz—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000133	0.000573	CcSEcCtD
Guanabenz—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000568	CcSEcCtD
Guanabenz—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000127	0.000548	CcSEcCtD
Guanabenz—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000126	0.000543	CcSEcCtD
Guanabenz—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000126	0.000543	CcSEcCtD
Guanabenz—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000528	CcSEcCtD
Guanabenz—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000525	CcSEcCtD
Guanabenz—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000122	0.000525	CcSEcCtD
Guanabenz—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000113	0.00049	CcSEcCtD
Guanabenz—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000111	0.000477	CcSEcCtD
Guanabenz—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00047	CcSEcCtD
Guanabenz—ADRA2C—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	0.000106	0.00283	CbGpPWpGaD
Guanabenz—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000105	0.000455	CcSEcCtD
Guanabenz—CYP1A2—Phase II conjugation—GSTP1—chronic obstructive pulmonary disease	0.000104	0.00277	CbGpPWpGaD
Guanabenz—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000102	0.000439	CcSEcCtD
Guanabenz—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	0.000102	0.00272	CbGpPWpGaD
Guanabenz—CYP1A2—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	9.95e-05	0.00266	CbGpPWpGaD
Guanabenz—Vomiting—Prednisone—chronic obstructive pulmonary disease	9.79e-05	0.000422	CcSEcCtD
Guanabenz—Rash—Prednisone—chronic obstructive pulmonary disease	9.71e-05	0.000419	CcSEcCtD
Guanabenz—Dermatitis—Prednisone—chronic obstructive pulmonary disease	9.7e-05	0.000419	CcSEcCtD
Guanabenz—Headache—Prednisone—chronic obstructive pulmonary disease	9.65e-05	0.000416	CcSEcCtD
Guanabenz—CYP1A2—Phase II conjugation—GSTM1—chronic obstructive pulmonary disease	9.53e-05	0.00255	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	9.52e-05	0.00255	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—APIP—chronic obstructive pulmonary disease	9.48e-05	0.00254	CbGpPWpGaD
Guanabenz—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	9.33e-05	0.0025	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	9.28e-05	0.00248	CbGpPWpGaD
Guanabenz—Nausea—Prednisone—chronic obstructive pulmonary disease	9.15e-05	0.000395	CcSEcCtD
Guanabenz—ADRA2C—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	8.9e-05	0.00238	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	8.75e-05	0.00234	CbGpPWpGaD
Guanabenz—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	8.72e-05	0.00233	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	8.67e-05	0.00232	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—GCLC—chronic obstructive pulmonary disease	8.65e-05	0.00231	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—CXCR2—chronic obstructive pulmonary disease	8.6e-05	0.0023	CbGpPWpGaD
Guanabenz—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	8.52e-05	0.00228	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—chronic obstructive pulmonary disease	8.4e-05	0.00225	CbGpPWpGaD
Guanabenz—ADRA2B—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	8.34e-05	0.00223	CbGpPWpGaD
Guanabenz—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRB2—chronic obstructive pulmonary disease	8.26e-05	0.00221	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TGFB2—chronic obstructive pulmonary disease	8.26e-05	0.00221	CbGpPWpGaD
Guanabenz—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	7.95e-05	0.00213	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.94e-05	0.00212	CbGpPWpGaD
Guanabenz—ADRA2C—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	7.79e-05	0.00208	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TGFB2—chronic obstructive pulmonary disease	7.71e-05	0.00206	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—APIP—chronic obstructive pulmonary disease	7.7e-05	0.00206	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	7.42e-05	0.00198	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—HDAC2—chronic obstructive pulmonary disease	7.41e-05	0.00198	CbGpPWpGaD
Guanabenz—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	7.3e-05	0.00195	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—SERPINA1—chronic obstructive pulmonary disease	7.23e-05	0.00193	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	7.21e-05	0.00193	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—chronic obstructive pulmonary disease	7.11e-05	0.0019	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	7.11e-05	0.0019	CbGpPWpGaD
Guanabenz—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRB2—chronic obstructive pulmonary disease	7.08e-05	0.00189	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	7.04e-05	0.00188	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	7.03e-05	0.00188	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	7.02e-05	0.00188	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—HDAC2—chronic obstructive pulmonary disease	6.92e-05	0.00185	CbGpPWpGaD
Guanabenz—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	6.81e-05	0.00182	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	6.74e-05	0.0018	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—PLAUR—chronic obstructive pulmonary disease	6.68e-05	0.00179	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	6.64e-05	0.00178	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	6.57e-05	0.00176	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	6.56e-05	0.00175	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—chronic obstructive pulmonary disease	6.53e-05	0.00175	CbGpPWpGaD
Guanabenz—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—chronic obstructive pulmonary disease	6.46e-05	0.00173	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	6.4e-05	0.00171	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—chronic obstructive pulmonary disease	6.4e-05	0.00171	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—chronic obstructive pulmonary disease	6.4e-05	0.00171	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	6.35e-05	0.0017	CbGpPWpGaD
Guanabenz—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	6.33e-05	0.00169	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	6.28e-05	0.00168	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	6.27e-05	0.00168	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—PLAUR—chronic obstructive pulmonary disease	6.24e-05	0.00167	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	6.15e-05	0.00165	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GC—chronic obstructive pulmonary disease	6.11e-05	0.00163	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	6.09e-05	0.00163	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	6.09e-05	0.00163	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	6.07e-05	0.00162	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	6.03e-05	0.00161	CbGpPWpGaD
Guanabenz—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.98e-05	0.0016	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	5.98e-05	0.0016	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	5.93e-05	0.00159	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.81e-05	0.00156	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	5.68e-05	0.00152	CbGpPWpGaD
Guanabenz—ADRA2B—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	5.67e-05	0.00152	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.62e-05	0.0015	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	5.62e-05	0.0015	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	5.57e-05	0.00149	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.56e-05	0.00149	CbGpPWpGaD
Guanabenz—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	5.54e-05	0.00148	CbGpPWpGaD
Guanabenz—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	5.5e-05	0.00147	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	5.47e-05	0.00146	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	5.43e-05	0.00145	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	5.39e-05	0.00144	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	5.33e-05	0.00143	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	5.32e-05	0.00142	CbGpPWpGaD
Guanabenz—ADRA2C—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	5.3e-05	0.00142	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	5.28e-05	0.00141	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	5.25e-05	0.0014	CbGpPWpGaD
Guanabenz—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	5.21e-05	0.00139	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	5.19e-05	0.00139	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	5.1e-05	0.00136	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	5.07e-05	0.00136	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	4.96e-05	0.00133	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	4.86e-05	0.0013	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	4.84e-05	0.00129	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	4.82e-05	0.00129	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—MMP1—chronic obstructive pulmonary disease	4.77e-05	0.00128	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—PLAU—chronic obstructive pulmonary disease	4.69e-05	0.00125	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	4.61e-05	0.00123	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	4.52e-05	0.00121	CbGpPWpGaD
Guanabenz—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.51e-05	0.00121	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—MMP1—chronic obstructive pulmonary disease	4.46e-05	0.00119	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	4.44e-05	0.00119	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	4.41e-05	0.00118	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—PLAU—chronic obstructive pulmonary disease	4.38e-05	0.00117	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—NOS2—chronic obstructive pulmonary disease	4.3e-05	0.00115	CbGpPWpGaD
Guanabenz—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	4.3e-05	0.00115	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	4.27e-05	0.00114	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	4.26e-05	0.00114	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	4.25e-05	0.00114	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	4.22e-05	0.00113	CbGpPWpGaD
Guanabenz—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	4.21e-05	0.00113	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	4.15e-05	0.00111	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—NOS2—chronic obstructive pulmonary disease	4.02e-05	0.00108	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	4.02e-05	0.00107	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.98e-05	0.00106	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.75e-05	0.001	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	3.67e-05	0.000982	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.65e-05	0.000976	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	3.62e-05	0.00097	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	3.62e-05	0.000969	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—ALB—chronic obstructive pulmonary disease	3.62e-05	0.000968	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.59e-05	0.00096	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	3.55e-05	0.000951	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—NOS3—chronic obstructive pulmonary disease	3.46e-05	0.000926	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.43e-05	0.000919	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.43e-05	0.000918	CbGpPWpGaD
Guanabenz—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	3.42e-05	0.000915	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	3.41e-05	0.000911	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	3.39e-05	0.000906	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—ALB—chronic obstructive pulmonary disease	3.38e-05	0.000904	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	3.37e-05	0.000901	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	3.35e-05	0.000897	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTT1—chronic obstructive pulmonary disease	3.34e-05	0.000893	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GCLC—chronic obstructive pulmonary disease	3.3e-05	0.000883	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	3.27e-05	0.000874	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.26e-05	0.000872	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	3.23e-05	0.000865	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—NOS3—chronic obstructive pulmonary disease	3.23e-05	0.000865	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	3.21e-05	0.000858	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	3.21e-05	0.000858	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	3.14e-05	0.00084	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	3.05e-05	0.000815	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	3.04e-05	0.000814	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.03e-05	0.000811	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CTGF—chronic obstructive pulmonary disease	3.01e-05	0.000805	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.93e-05	0.000785	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.85e-05	0.000763	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.82e-05	0.000753	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.77e-05	0.000742	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	2.77e-05	0.00074	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	2.75e-05	0.000736	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	2.74e-05	0.000734	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	2.74e-05	0.000733	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	2.72e-05	0.000728	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	2.71e-05	0.000725	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	2.68e-05	0.000717	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.66e-05	0.000712	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	2.63e-05	0.000702	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	2.61e-05	0.000697	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	2.6e-05	0.000697	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.55e-05	0.000681	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.51e-05	0.000672	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—VEGFA—chronic obstructive pulmonary disease	2.49e-05	0.000667	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	2.47e-05	0.000662	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	2.45e-05	0.000654	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	2.38e-05	0.000637	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	2.35e-05	0.000628	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.33e-05	0.000625	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—VEGFA—chronic obstructive pulmonary disease	2.33e-05	0.000623	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTP1—chronic obstructive pulmonary disease	2.31e-05	0.000619	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TGFB1—chronic obstructive pulmonary disease	2.29e-05	0.000612	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—HMOX1—chronic obstructive pulmonary disease	2.28e-05	0.00061	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	2.25e-05	0.000603	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KL—chronic obstructive pulmonary disease	2.18e-05	0.000583	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	2.16e-05	0.000579	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.15e-05	0.000576	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TGFB1—chronic obstructive pulmonary disease	2.14e-05	0.000572	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTM1—chronic obstructive pulmonary disease	2.13e-05	0.000569	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.03e-05	0.000543	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP1A1—chronic obstructive pulmonary disease	2.02e-05	0.000539	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	2.01e-05	0.000538	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.94e-05	0.000519	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.93e-05	0.000515	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.91e-05	0.00051	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	1.89e-05	0.000506	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TP53—chronic obstructive pulmonary disease	1.88e-05	0.000504	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.88e-05	0.000503	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.85e-05	0.000496	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.81e-05	0.000485	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.8e-05	0.000481	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	1.77e-05	0.000474	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.76e-05	0.000471	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TP53—chronic obstructive pulmonary disease	1.76e-05	0.000471	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.75e-05	0.000468	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	1.74e-05	0.000464	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.73e-05	0.000462	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.68e-05	0.000451	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.65e-05	0.00044	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.64e-05	0.000438	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.63e-05	0.000437	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	1.63e-05	0.000437	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.57e-05	0.000421	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.57e-05	0.000419	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.5e-05	0.0004	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	1.48e-05	0.000396	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	1.47e-05	0.000394	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.46e-05	0.000391	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	1.46e-05	0.000391	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	1.43e-05	0.000382	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.38e-05	0.000369	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ALB—chronic obstructive pulmonary disease	1.37e-05	0.000366	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	1.35e-05	0.000361	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	1.34e-05	0.000358	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	1.33e-05	0.000355	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—NOS3—chronic obstructive pulmonary disease	1.31e-05	0.000351	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.29e-05	0.000344	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	1.28e-05	0.000342	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.23e-05	0.000329	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	1.2e-05	0.000322	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	1.19e-05	0.000318	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.17e-05	0.000314	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	1.15e-05	0.000307	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	1.11e-05	0.000298	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	1.1e-05	0.000293	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	1.06e-05	0.000285	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	1.04e-05	0.000278	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.04e-05	0.000277	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.02e-05	0.000274	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.89e-06	0.000265	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	9.77e-06	0.000261	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.72e-06	0.00026	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.53e-06	0.000255	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	9.41e-06	0.000252	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	9.32e-06	0.000249	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	9.24e-06	0.000247	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.04e-06	0.000242	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	8.9e-06	0.000238	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.79e-06	0.000235	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	8.45e-06	0.000226	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7.89e-06	0.000211	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.89e-06	0.000211	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.76e-06	0.000208	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.61e-06	0.000203	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	7.51e-06	0.000201	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.25e-06	0.000194	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	7.14e-06	0.000191	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	7.1e-06	0.00019	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	6.41e-06	0.000172	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	6.39e-06	0.000171	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	6.14e-06	0.000164	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.96e-06	0.00016	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.89e-06	0.000157	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	5.88e-06	0.000157	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.85e-06	0.000156	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.77e-06	0.000154	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.46e-06	0.000146	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.84e-06	0.00013	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	4.43e-06	0.000119	CbGpPWpGaD
